Zealand Pharma AS (OCSE:ZEAL) EPS (Basic) : kr-16.75 (TTM As of Sep. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Zealand Pharma AS EPS (Basic)?

Zealand Pharma AS's basic earnings per share (Basic EPS) for the three months ended in Sep. 2024 was kr-3.77. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was kr-16.75.

Zealand Pharma AS's EPS (Diluted) for the three months ended in Sep. 2024 was kr-3.77. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was kr-16.75.

Zealand Pharma AS's EPS without NRI for the three months ended in Sep. 2024 was kr-4.31. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was -15.21.

During the past 3 years, the average EPS without NRI Growth Rate was 16.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 9.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was -14.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Zealand Pharma AS's highest 3-Year average EPS without NRI Growth Rate was 16.80% per year. The lowest was -61.20% per year. And the median was -15.85% per year.

Zealand Pharma AS EPS (Basic) Historical Data

The historical data trend for Zealand Pharma AS's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma AS EPS (Basic) Chart

Zealand Pharma AS Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-16.91

-22.07

-23.75

-26.02

-12.44

Zealand Pharma AS Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EPS (Basic)	Get a 7-Day Free Trial															1.27	-4.60	-3.71	-4.67	-3.77

Zealand Pharma AS EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Zealand Pharma AS's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-703.739	-	0)	/	56.589
	=	-12.44

Zealand Pharma AS's Basic EPS for the quarter that ended in Sep. 2024 is calculated as

Basic EPS (Q: Sep. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-266.396	-	0)	/	70.662
	=	-3.77

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-16.75

Zealand Pharma AS (OCSE:ZEAL) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Zealand Pharma AS EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Zealand Pharma AS's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Zealand Pharma AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma AS (OCSE:ZEAL) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

ZLDPF:USA ZEALc:UK 0NZU:UK 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.